Dulera Dosing for a 9-Year-Old with Persistent Asthma
For a 9-year-old child with persistent asthma experiencing exacerbations during bronchitis, start with Dulera 50 mcg/5 mcg (mometasone/formoterol), two inhalations twice daily (morning and evening), which is the only FDA-approved dose for children aged 5 to less than 12 years 1.
Dosing Algorithm by Age
For Children 5 to <12 Years (Your Patient)
- Dose: Dulera 50 mcg/5 mcg, 2 inhalations twice daily
- Maximum daily dose: 200 mcg/20 mcg total
- This is the only approved strength for this age group 1
For Adolescents ≥12 Years
- Starting dose: Dulera 100 mcg/5 mcg OR 200 mcg/5 mcg, 2 inhalations twice daily
- Choose strength based on disease severity and previous ICS dose
- If inadequate response after 2 weeks on 100 mcg/5 mcg, increase to 200 mcg/5 mcg
- Maximum daily dose: 800 mcg/20 mcg (two inhalations of 200 mcg/5 mcg twice daily) 1
Critical Administration Instructions
Proper technique is essential:
- Shake well before each inhalation
- Prime with 4 test sprays if first use or not used for >5 days 1
- Rinse mouth with water and spit out after each dose to reduce risk of oral candidiasis 1
- Use short-acting beta-agonist (albuterol) for acute symptoms between doses 1
Rationale for ICS/LABA Combination in This Patient
This 9-year-old has moderate persistent asthma (evidenced by exacerbations during viral illnesses). The combination of inhaled corticosteroid plus long-acting beta-agonist is preferred over ICS monotherapy for moderate persistent asthma in children 5-11 years 2.
Key evidence supporting combination therapy:
- Multiple studies demonstrate ICS/LABA combinations provide superior asthma control compared to doubling ICS dose alone in children 3, 4, 5
- The VIAPAED trial showed adding salmeterol to low-dose ICS was more effective than doubling ICS dose in children 4-16 years, with 8.7% more symptom-free days 5
- Combination therapy provides better protection against exercise-induced bronchospasm 6
Important Safety Considerations
Never use LABA as monotherapy - LABAs must always be combined with ICS due to increased risk of severe exacerbations and deaths when used alone 2, 7, 1. Dulera addresses this by combining both medications in one inhaler.
Monitor for:
- Oral candidiasis (treat locally while continuing therapy) 1
- Growth velocity (ICS can cause small, non-progressive reduction) 2
- Adrenal suppression if using high doses or during stress 1
- Cardiovascular effects (tachycardia, tremor) from formoterol 1
Management During Viral Exacerbations
For acute exacerbations during bronchitis episodes:
- Continue Dulera as maintenance therapy
- Add short-acting beta-agonist (albuterol) for immediate relief 1
- Consider short course of oral corticosteroids (prednisolone 1-2 mg/kg/day, maximum 40 mg, for 3-10 days) for moderate-severe exacerbations 2
- No taper needed for short courses 7
Titration Strategy
After achieving asthma stability, titrate to the lowest effective dose to minimize side effects 1. Reassess every 4-6 weeks initially 2. If control is inadequate on Dulera 50 mcg/5 mcg after appropriate trial, the patient would need to transition to adolescent dosing (100 mcg/5 mcg) once they turn 12 years old, as higher doses are not approved for children under 12 1.
Common pitfall: Do not add another LABA (like separate salmeterol or formoterol) for exercise-induced symptoms while on Dulera - this doubles LABA exposure and increases cardiovascular risks 1. Use short-acting beta-agonist instead.